| 张新胜 张宏玲 郑义 黄来强.壳聚糖介导CrmA基因治疗小鼠肝纤维化的研究[J].,2014,14(9):1601-1605 |
| 壳聚糖介导CrmA基因治疗小鼠肝纤维化的研究 |
| Gene Therapy for Mouse Hepatic Fibrosiswith Chitosan-mediated CrmA |
| |
| DOI： |
| 中文关键词: 肝纤维化 细胞因子反应调节蛋白A 白介素-1beta 壳聚糖 基因治疗 |
| 英文关键词: Liver fibrosis Cytokine response modifier A IL-1beta Chitosan Gene therapy |
| 基金项目:国家自然科学基金项目(30570960)；广东省自然科学基金(05010197)；深圳市重点实验室建设与提升计划 |
|
| 摘要点击次数: 755 |
| 全文下载次数: 934 |
| 中文摘要: |
| 目的：探讨壳聚糖介导的CrmA对小鼠肝纤维化的治疗效果，以期为肝纤维化的基因治疗提供实验基础。方法：清洁级的
75 只雄性小鼠随机分为正常组、模型组、壳聚糖介导的CrmA组、壳聚糖介导的空载体组、壳聚糖组，每组15只。应用30 %四氯
化碳橄榄油溶液3 ml/kg腹腔注射制备肝纤维化小鼠模型。治疗8 周后，眼眶取血，检测血清的肝功能指标，并取肝组织做HE 染
色，观察各组小鼠肝脏的病理形态，Real Time PCR 检测肝组织IL-1beta、alpha-SMA、TGF-beta1、TIMP-1 表达量。结果：与模型组小鼠相
比，壳聚糖介导的CrmA组小鼠的肝纤维化程度减轻，ALT、AST 显著降低（P<0.01），肝组织IL-1beta、alpha-SMA、TIMP1、TGF-beta1 的表
达明显减少（P<0.05），而模型组、壳聚糖介导的空载体组和壳聚糖组均无显著性差异。结论：壳聚糖介导的CrmA能有效减轻肝
纤维化小鼠的肝脏损伤和纤维化程度，为基因治疗肝纤维化提供了一种潜在的新思路和方法。 |
| 英文摘要: |
| Objective:To explore the therapeutic effects of the chitosan-mediated CrmA on CCl4-induced hepatic fibrosis in
mouse.Methods:Seventy five male mice of clean grade were divided evenly into five groups marked "Normal", "Model", "chitosan-mediated
CrmA", "chitosan-mediated vector" and "Chitosan". Liver fibrosis model mice were given 30 % carbon tetrachloride olive oil
solution 3 ml/kg by intraperitoneal injection. After eight weeks of treatment, hepatic fibrosis was evaluated through measuring serum
ALT and AST, examining HE pigmentation, and determining by Real Time PCR the expression levels of IL-1beta, alpha-SMA, TGF-beta1 and
TIMP-1 in hepatic tissue.Results:Compared with the model group, the degree of liver fibrosis in the chitosan-mediated CrmA group was
obviously reduced. The ALT and AST levels of the chitosan-mediated CrmA group were much lower than that of model group (P<0.01).
The mRNA expression of IL-1beta, alpha-SMA and TIMP-1 was reduced markedly in the chitosan-mediated CrmA group (P<0.05), as
compared with the model group, whereas no significant difference was observed among the chitosan-mediated vector group, chitosan
group and model group (P>0.05).Conclusion:The chitosan-mediated CrmA had therapeutic effects of easing the liver damage and
hepatic fibrosis condition in the mouse model and provides a potential new approach for the treatment of liver fibrosis. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
